Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
SVRA
Savara Inc.
NASDAQGS
Biotechnology
United States
$5.37
—
+0.00 (+0.00%)
CLOSED
—
OPEN
$5.32
HIGH
$5.39
LOW
$5.31
PREV CLOSE
$5.37
VOLUME
625.2K
0.35x avg
BID / ASK
3.87 / 6.87
spr 3.000
MARKET CAP
$1.10B
DAY RANGE
$5.31
$5.39
P/E (TTM)
—
Fwd -17.2
EPS (TTM)
-0.58
DIV YIELD
—
52W HIGH
$7.01
-23.3%
52W LOW
$3.34
+60.8%
BETA
0.25
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$5.39
+0.02
(+0.37%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
SVRA
$5.37
▲
+0.00%
Chart
Valuation
Financials
Peers
News
SVRA · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +44.4% YOY
1-year price chart. Started at 3.72, currently 5.37, up 44.4 percent. Range 3.37 to 6.94 over 252 data points.
2025-09-05
$3.72 → $5.37 (+44.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables skipped: no peer multiples or no per-share economics from Finnhub metric endpoint.
FINANCIALS
多年財務（SEC XBRL）
—
4 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$118.8M
-$101.0M
-$101.1M
$253.4M
2024-12
—
-$95.9M
-$89.1M
-$89.1M
$212.9M
2023-12
—
-$54.7M
-$51.1M
-$51.4M
$177.6M
2020-12
$257.0K
—
—
—
—
NEWS
近期新聞（過去 14 天）
CALM
10 HEADLINES · LAST 14 DAYS
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire · 2026-08-24
Savara Announces New Employment Inducement Grant
Business Wire · 2026-08-20
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · 2026-08-11
What Insmed Stock's Premium Is Actually Buying
Trefis · 2026-08-07
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Business Wire · 2026-07-30
Here's Why You Should Add Savara Stock to Your Portfolio Now
Zacks · 2026-07-22
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
GlobeNewswire · 2026-06-30
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
Motley Fool · 2026-06-27